Multiple Sclerosis
Also known as: MS
Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord. This demyelination disrupts communication between the brain and the body, leading to a wide range of neurological symptoms. MS most commonly appears between ages 20 and 40 and is more prevalent in women.
Last updated November 10, 2026
Understanding Multiple Sclerosis
Multiple sclerosis (MS) is a chronic immune-mediated disease in which the body's own white cells attack the myelin insulation and, eventually, the nerve fibers of the brain, spinal cord and optic nerves. It is the most common disabling neurological disease of young adults. A 2019 prevalence study estimated about 913,000 adults living with MS in the United States, roughly double earlier figures, and the global count is about 2.9 million. Women are affected nearly three times as often as men, onset clusters between 20 and 40, and risk rises with distance from the equator, with low vitamin D, with smoking, with adolescent obesity and, most strikingly, after Epstein-Barr virus infection. Black Americans are diagnosed at least as often as white Americans and tend to have a more aggressive course. About 85 percent begin with relapsing-remitting disease; 10 to 15 percent have primary progressive MS, which steadily worsens from the start and begins about a decade later.
The trigger that sets the immune system against myelin is now thought to be Epstein-Barr virus. In a 2022 study of 10 million US military personnel, MS risk rose 32-fold after EBV infection and not after any other virus, and the first signs of nerve damage in the blood appeared only after seroconversion. Once activated, T and B cells cross into the central nervous system and strip myelin in patches, producing the lesions seen on MRI and symptoms that depend on location: optic neuritis, numbness, weakness, double vision, vertigo or bladder trouble. A relapse evolves over days, plateaus and then recovers over weeks as inflammation settles and some myelin is repaired. Beneath the relapses, slower 'smoldering' inflammation and loss of axons accumulate, which is what eventually drives progression. Before modern therapy, about half of people needed a cane within 15 to 20 years; cohorts treated early with effective drugs now progress far more slowly, and many never reach that point.
More than 20 disease-modifying therapies (DMTs) are now approved, and the central decision is how strong to start. Injectable interferons and glatiramer reduce relapses by about 30 percent; oral drugs such as dimethyl fumarate, teriflunomide and the S1P modulators by 35 to 55 percent; and high-efficacy agents further still. Ocrelizumab, a B-cell-depleting antibody, cut relapses by 46 to 47 percent compared with interferon in the OPERA trials and was the first drug to slow primary progressive MS (a 24 percent reduction in confirmed disability progression in ORATORIO); natalizumab cut relapses by 68 percent versus placebo; ofatumumab, cladribine and alemtuzumab sit in the same tier. Large observational comparisons have pushed the field toward early high-efficacy treatment for most people rather than escalating after failure. Relapses that impair function are treated with 3 to 5 days of high-dose methylprednisolone, which speeds recovery without changing its extent. Symptom care for spasticity, fatigue, bladder, pain and depression, and rehabilitation, are as important as the DMT to day-to-day life.
No supplement, herb or diet modifies the course of MS, and several that are heavily promoted have failed properly run trials. High-dose biotin (300 mg a day) looked promising in a small study but did nothing in the 642-person SPI2 trial and, worse, interferes with thyroid and troponin blood tests. Omega-3 fish oil had no effect on MRI activity or relapses in the OFAMS trial. Ginkgo did not improve cognition in a 120-person trial. Vitamin D is the exception that proves the rule: low levels clearly predict higher risk and more MRI activity, and in the 2025 D-Lay MS trial 100,000 IU every 2 weeks reduced disease activity in people with a first demyelinating event who were not yet on a DMT, but three earlier trials adding high doses to interferon or glatiramer showed little or nothing, so vitamin D is best seen as a reasonable floor rather than a therapy. Alpha-lipoic acid slowed brain atrophy in one 51-person trial awaiting confirmation. Acetyl-L-carnitine and coenzyme Q10 have small trials for fatigue. Check vitamin B12, since deficiency mimics and worsens MS.
The most common mistake is stopping or delaying disease-modifying therapy because you feel well. MS is quietest in exactly the years when treatment prevents the most damage, and the relapses and MRI lesions that follow a drug holiday cannot be undone; stopping natalizumab in particular can cause rebound worse than the original disease. People stop for understandable reasons, such as needle fatigue, worries about infection, cost, pregnancy plans or a persuasive diet book, and almost all of them have a better solution than quitting, from switching to a twice-yearly infusion to timing therapy around conception. A related mistake is treating every bad day as a relapse. A true relapse brings new or clearly worse symptoms lasting more than 24 hours without fever; a pseudo-relapse is old symptoms resurfacing with heat, infection, poor sleep or stress, and it clears when the cause does. Check for a urine infection before assuming the disease has moved.
At a Glance
- Common symptoms
- Numbness or tingling in the limbs, face, or trunk, Muscle weakness or spasticity, Vision problems including optic neuritis and double vision
- Main treatments
- Disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, ocrelizumab, natalizumab), High-dose corticosteroids for acute relapses, Physical and occupational therapy
- Category
- Autoimmune · Nearly 1 million adults in the US; about 2.8 million worldwide
- See a doctor if
- New onset of numbness, weakness, or visual changes
Symptoms
Causes
- Autoimmune attack on central nervous system myelin
- Genetic susceptibility involving multiple genes (HLA-DRB1)
- Environmental factors including low vitamin D and EBV infection
- Immune dysregulation with T-cell and B-cell involvement
Risk Factors
- Female sex (2–3 times more common in women)
- Age 20–40 at onset
- Northern European ancestry and living at higher latitudes
- History of Epstein-Barr virus infection
- Low vitamin D levels
- Smoking
Diagnosis
- MRI of the brain and spinal cord showing demyelinating lesions
- Lumbar puncture revealing oligoclonal bands in cerebrospinal fluid
- Evoked potential tests measuring nerve signal speed
- McDonald criteria for dissemination in space and time
- Blood tests to rule out other conditions
Treatment
- Disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, ocrelizumab, natalizumab)
- High-dose corticosteroids for acute relapses
- Physical and occupational therapy
- Symptom management (baclofen for spasticity, modafinil for fatigue, bladder medications)
- Rehabilitation programs for cognitive and physical function
Natural remedies for multiple sclerosis: what the evidence says
Ranked by the strength of human evidence for multiple sclerosis specifically. These sit alongside medical care, not in place of it.
Vitamin D
Moderate evidenceLow 25-hydroxyvitamin D is linked to higher MS risk and, in people already diagnosed, to more relapses and new MRI lesions. In the D-Lay MS trial (303 people with a first demyelinating event, no DMT), 100,000 IU of cholecalciferol every 2 weeks for 2 years reduced the proportion with disease activity from 74 to 60 percent. But when high doses were added to interferon or glatiramer in the SOLAR (229 people, 14,000 IU daily), CHOLINE (129 people) and VIDAMS (172 people, 5,000 versus 600 IU) trials, relapse rates did not fall significantly, though some MRI measures improved. The honest reading is that correcting deficiency is worthwhile and may matter most early; it is not a substitute for a DMT.
- Studied dose
- 2,000 to 4,000 IU vitamin D3 daily, adjusted to keep 25-hydroxyvitamin D roughly between 40 and 60 ng/mL (100 to 150 nmol/L); many neurologists check the level yearly.
- Cautions
- Sustained intakes above 10,000 IU a day can cause high calcium and kidney stones, and a few MS patients following unsupervised ultra-high-dose protocols have developed kidney injury. Avoid combining with calcium megadoses or thiazides without monitoring.
Alpha-Lipoic Acid
Preliminary evidenceIn a 2-year placebo-controlled trial of 51 people with secondary progressive MS, 1,200 mg of alpha-lipoic acid daily reduced the annual rate of whole-brain atrophy by 68 percent (0.21 versus 0.65 percent a year) and showed a trend toward better walking speed. The trial was small and used brain volume, not disability, as its endpoint; a larger confirmatory trial has since been run, and until its results are fully published the finding should be treated as a hypothesis. It has no evidence in relapsing MS.
- Studied dose
- 1,200 mg of racemic alpha-lipoic acid once daily on an empty stomach, the form and dose used in the trial.
- Cautions
- Causes stomach upset and, rarely, rash; it can lower blood sugar in people on insulin or sulfonylureas and has been linked to a rare autoimmune low-glucose syndrome in people of East Asian ancestry. The trial dose is well above typical supplement amounts.
Acetyl-L-Carnitine
Preliminary evidenceFatigue affects about 80 percent of people with MS and responds poorly to drugs. In a crossover trial of 36 people, 1 g of acetyl-L-carnitine twice daily for 3 months reduced fatigue scores at least as much as amantadine with fewer side effects; a later 60-person trial comparing it with amantadine, modafinil and placebo found no clear benefit for any of them, so the evidence is mixed. It is a reasonable short trial for someone whose fatigue persists after sleep, depression, anemia, thyroid and vitamin D have been checked.
- Studied dose
- 1 g of acetyl-L-carnitine twice daily for 8 to 12 weeks; stop if there is no clear benefit.
- Cautions
- Can cause nausea, restlessness and a fishy body odor; it may enhance the effect of warfarin and can blunt thyroid hormone, so mention it if you take levothyroxine.
Coenzyme Q10
Preliminary evidenceA 12-week placebo-controlled trial in 48 people with relapsing-remitting MS found 500 mg of coenzyme Q10 daily reduced fatigue and depression scores and lowered markers of oxidative stress, and a second trial from the same group reported lower inflammatory cytokines. No trial has looked at relapses, MRI activity or disability, so the plausible benefit is limited to fatigue, and the effect size in such a small study is uncertain.
- Studied dose
- 500 mg of coenzyme Q10 (ubiquinone or ubiquinol) daily with a meal containing fat, for at least 12 weeks.
- Cautions
- Can reduce the effect of warfarin and lower blood pressure slightly; mild insomnia and stomach upset occur at higher doses. It is expensive for an uncertain benefit.
Vitamin B12
Preliminary evidenceB12 deficiency damages the same spinal cord tracts as MS, causing numbness, unsteadiness and fatigue that can be mistaken for progression, and it is more common in people with MS than expected, partly because of shared autoimmunity with pernicious anemia and partly because of metformin and acid-suppressing drugs. Older trials of B12 injections in non-deficient patients showed no benefit on disability, so supplementation is for correcting a documented low level, which every person with MS should have checked at diagnosis and periodically after.
- Studied dose
- If deficient: 1,000 mcg oral B12 daily, or injections if absorption is the problem, until the level and methylmalonic acid normalize.
- Cautions
- Essentially non-toxic. The pitfall is the opposite: taking it without a test and missing the fact that your level is already normal and the symptoms are something else.
What matters day to day
- Quit smoking: in a Swedish cohort, each year of continued smoking after diagnosis brought secondary progression forward by nearly 5 percent, and quitters progressed at the rate of never-smokers; smoking also makes neutralizing antibodies to interferon and natalizumab more likely.
- Exercise regularly, combining aerobic work and resistance training 2 to 3 times a week: Cochrane and later reviews show improved walking, strength and fatigue with no increase in relapses, and it is the only intervention that consistently helps MS fatigue.
- Manage heat: a rise in core temperature of as little as 0.5 degrees C can temporarily worsen symptoms (Uhthoff's phenomenon), so use cooling vests, cold drinks, air conditioning and morning exercise, and do not mistake a hot-weather dip for a relapse.
- Keep vaccinations current and time them well: inactivated vaccines are safe in MS, but B-cell therapies such as ocrelizumab blunt the response, so get flu, COVID, pneumococcal and shingles vaccines at least 2 to 4 weeks before a dose or toward the end of a cycle.
- Protect sleep and screen for depression: both affect about half of people with MS, both amplify fatigue and cognitive complaints, and both are treatable; untreated depression is the strongest predictor of poor quality of life in MS.
- Eat a Mediterranean-style pattern and keep weight in range: no diet has been shown to modify MS, but higher Mediterranean diet adherence is linked to lower disability and less brain atrophy in cohort studies, and obesity worsens inflammation and treatment response.
Prevention
- No proven way to prevent MS, but modifiable risk factors include:
- Maintaining adequate vitamin D levels
- Not smoking or quitting smoking
- Maintaining a healthy weight
When to See a Doctor
- New onset of numbness, weakness, or visual changes
- Rapid worsening of existing neurological symptoms (possible relapse)
- Sudden loss of vision in one eye
- Significant changes in bladder or bowel function
Frequently Asked Questions
References
- Wallin MT, Culpepper WJ, Campbell JD, et al.. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology (2019)
- Bjornevik K, Cortese M, Healy BC, et al.. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science (2022)
- Rae-Grant A, Day GS, Marrie RA, et al.. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology (2018)
- Hauser SL, Bar-Or A, Comi G, et al.. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine (2017)
- Cree BAC, Cutter G, Wolinsky JS, et al.. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology (2020)
- Thouvenot E, Laplaud D, Lebrun-Frenay C, et al.. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA (2025)
- Torkildsen O, Wergeland S, Bakke S, et al.. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Archives of Neurology (2012)
- Spain R, Powers K, Murchison C, et al.. Lipoic acid in secondary progressive MS: A randomized controlled pilot trial. Neurology: Neuroimmunology & Neuroinflammation (2017)
- Ramanujam R, Hedström AK, Manouchehrinia A, et al.. Effect of Smoking Cessation on Multiple Sclerosis Prognosis. JAMA Neurology (2015)
- National Institute of Neurological Disorders and Stroke. Multiple Sclerosis (2024)View source
Related Conditions
Related from the Supplement Library
Vitamin D
StrongVitamin · Bone health and calcium absorption
Omega-3 (EPA/DHA)
StrongFatty Acid · Cardiovascular health (TG reduction, anti-arrhythmic)
Alpha-Lipoic Acid (ALA)
StrongCompound · Universal antioxidant (fat and water soluble)
Probiotics (Lactobacillus)
StrongProbiotic · Gut microbiome balance and diversity
CoQ10 (Ubiquinone)
StrongCompound · Mitochondrial energy production (ATP)
These supplements have been studied in relation to Multiple Sclerosis. Always consult your healthcare provider before starting any supplement, especially if you take medications.
Have questions about Multiple Sclerosis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.